Although our cohort predominantly included ER+ breast cancer patients, with approximately 60% evaluated at the onset of metastatic treatment, the distribution of ctDNA estimates closely mirrored those reported in ref.42. The gene discussed is ESR1; the disease is breast carcinoma.